Technologies for deriving primary tumor cells for use in personalized cancer therapy

Trends in Biotechnology

Volumn 31, Issue 6, 2013, Pages 347-354

  Mitra, Abhisek ^a   Mishra, Lopa ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Personalized therapy; Primary tumor cell lines

Indexed keywords

BIOMIMETIC SCAFFOLDS; CANCER CELL LINES; CHEMICALLY DEFINED MEDIAS; ESSENTIAL NUTRIENTS; PERSONALIZED THERAPIES; POTENTIAL EFFICACY; SHORT-TERM CULTURES; TUMOR CELL LINES;

BIOGRAPHIES; BIOMIMETICS; CELL CULTURE; ONCOLOGY; TUMORS;

SCAFFOLDS (BIOLOGY);

BIOMIMETIC MATERIAL; COLLAGENASE; DEOXYRIBONUCLEASE; ELASTASE; HYALURONIDASE; PAPAIN; PRONASE; TRYPSIN;

ACCURACY; CANCER STEM CELL; CANCER THERAPY; CELL CULTURE; CELL ISOLATION; CELL SUSPENSION; CELL VIABILITY; CULTURE MEDIUM; CULTURE TECHNIQUE; ENZYMATIC DEGRADATION; ENZYME DEGRADATION; EXPLANT; EXTRACELLULAR MATRIX; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; MONOLAYER CULTURE; NONHUMAN; NUCLEAR REPROGRAMMING; NUTRIENT SUPPLY; PERSONALIZED MEDICINE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STROMA CELL; TUMOR CELL; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR NECROSIS;

CELL CULTURE TECHNIQUES; CULTURE MEDIA; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84878161769     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.03.006     Document Type: Review

References (78)

1. Zhou B.B., et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8:806-823.
2. (2000) Cancer multidrug resistance. Nat. Biotechnol. 18, IT18-IT20.
3. Gillet J.P., et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18708-18713.
4. Gazdar A.F., et al. Lung cancer cell lines: useless artifacts or invaluable tools for medical science?. Lung Cancer 2010, 68:309-318.
5. Kirk R. Genetics: personalized medicine and tumour heterogeneity. Nat. Rev. Clin. Oncol. 2012, 9:250.
6. Lima S.C., et al. Epigenetic signatures in cancer: implications for the control of cancer in the clinic. Curr. Opin. Mol. Ther. 2010, 12:316-324.
7. Toyota M., Issa J.P. Epigenetic changes in solid and hematopoietic tumors. Semin. Oncol. 2005, 32:521-530.
8. Schilsky R.L. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 2010, 9:363-366.
9. Mitsiades C.S., et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J. Clin. Oncol. 2011, 29:1916-1923.
10. Trusheim M.R., et al. Quantifying factors for the success of stratified medicine. Nat. Rev. Drug Discov. 2011, 10:817-833.
11. Chopra D.P., et al. Isolation and characterization of epithelial cell types from the normal rat colon. Cancer Res. 1981, 41:168-175.
12. McCallum H.M., Lowther G.W. Long-term culture of primary breast cancer in defined medium. Breast Cancer Res. Treat. 1996, 39:247-259.
13. Castell J.V., Gomez-Lechon M.J. Liver cell culture techniques. Methods Mol. Biol. 2009, 481:35-46.
14. Burdall S.E., et al. Breast cancer cell lines: friend or foe?. Breast Cancer Res. 2003, 5:89-95.
15. Gazdar A.F., et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 1998, 78:766-774.
16. Wurdak H., et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 2010, 6:37-47.
17. Dhanabal M., et al. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 1999, 274:11721-11726.
18. Ljung B.M., et al. Cell dissociation techniques in human breast cancer - variations in tumor cell viability and DNA ploidy. Breast Cancer Res. Treat. 1989, 13:153-159.
19. Mitaka T. The current status of primary hepatocyte culture. Int. J. Exp. Pathol. 1998, 79:393-409.
20. Li W.C., et al. Isolation and culture of adult mouse hepatocytes. Methods Mol. Biol. 2010, 633:185-196.
21. Mitra R., Morad M. A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. Am. J. Physiol. 1985, 249:H1056-H1060.
22. Harris C.C., Leone C.A. Some effects of EDTA and tetraphenylboron on the ultrastructure of mitochondria in mouse liver cells. J. Cell Biol. 1996, 28:405-408.
23. Goodenough D.A., Gilula N.B. The splitting of hepatocyte gap junctions and zonulae occludentes with hypertonic disaccharides. J. Cell Biol. 1974, 61:575-590.
24. Cunningham R.E. Tissue disaggregation. Methods Mol. Biol. 2010, 588:327-330.
25. Kurz H., et al. On the bifurcation of blood vessels - Wilhelm Roux's doctoral thesis (Jena 1878) - a seminal work for biophysical modelling in developmental biology. Ann. Anat. 1997, 179:33-36.
26. Soule H.D., et al. Phenotypic variance among cells isolated from spontaneous mouse mammary tumors in primary suspension culture. Cancer Res. 1981, 41:1154-1164.
27. Roskelley C.D., et al. A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr. Opin. Cell Biol. 1995, 7:736-747.
28. Pei X.F., et al. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell. Dev. Biol. Anim. 2004, 40:14-21.
29. Bull N., et al. Organotypic explant culture of adult rat retina for in vitro investigations of neurodegeneration, neuroprotection and cell transplantation. Protoc. Exchange 2011, 10.1038/protex.2011.215.
30. Parajuli N., Doppler W. Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs. In Vitro Cell. Dev. Biol. Anim. 2009, 45:442-450.
31. Kim J.B., et al. Three-dimensional in vitro tissue culture models of breast cancer - a review. Breast Cancer Res. Treat. 2004, 85:281-291.
32. Jechlinger M., et al. Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev. 2009, 23:1677-1688.
33. Malinen M.M., et al. Peptide nanofiber hydrogel induces formation of bile canaliculi structures in three-dimensional hepatic cell culture. Tissue Eng. Part A 2012, 18:2418-2425.
34. Fischbach C., et al. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
35. Berdichevsky F., et al. Branching morphogenesis of human mammary epithelial cells in collagen gels. J. Cell Sci. 1994, 107:3557-3568.
36. Fridman R., et al. Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection. Nat. Protoc. 2012, 7:1138-1144.
37. Smith B.H., et al. Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res. 2011, 71:716-724.
38. Li M.L., et al. Influence of a reconstituted basement membrane and its components on casein gene expression and secretion in mouse mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:136-140.
39. Fridman R., et al. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J. Natl. Cancer Inst. 1991, 83:769-774.
40. Kenny P.A., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1:84-96.
41. Wang S., et al. Three-dimensional primary hepatocyte culture in synthetic self-assembling peptide hydrogel. Tissue Eng. Part A 2008, 14:227-236.
42. Dairkee S.H., et al. Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells. Cancer Res. 1997, 57:1590-1596.
43. Jones J.C. Reduction of contamination of epithelial cultures by fibroblasts. CSH Protoc. 2008, 10.1101/pdb.prot4478.
44. Dairkee S.H., et al. Selective cell culture of primary breast carcinoma. Cancer Res. 1995, 55:2516-2519.
45. Yang Z.F., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
46. Chiba T., et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
47. Iliopoulos D., et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:1397-1402.
48. Battula V.L., et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J. Clin. Invest. 2012, 122:2066-2078.
49. Stuelten C.H., et al. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 2010, 28:649-660.
50. Gemei M., et al. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer 2013, 119:729-738.
51. Li C., et al. Identification of human pancreatic cancer stem cells. Methods Mol. Biol. 2009, 568:161-173.
52. Schepers A.G., et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
53. Clement V., et al. Marker-independent identification of glioma-initiating cells. Nat. Methods 2010, 7:224-228.
54. Liu X., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 2012, 180:599-607.
55. Suzuki-Anekoji M., et al. HNK-1 glycan functions as a tumor suppressor for astrocytic tumor. J. Biol. Chem. 2011, 286:32824-32833.
56. Canela A., et al. High-throughput telomere length quantification by FISH and its application to human population studies. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5300-5305.
57. Navin N., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
58. Gaur P., et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011, 141:1728-1737.
59. Singh S.K., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
60. Cheon D.J., Orsulic S. Mouse models of cancer. Annu. Rev. Pathol. 2011, 6:95-119.
61. Torzilli G., et al. Total or partial anatomical resection of segment 8 using the ultrasound-guided finger compression technique. HPB (Oxford) 2011, 13:586-591.
62. Ayabe T., et al. Emergent completion pneumonectomy for postoperative hemorrhage from rupture of the infected pulmonary artery in lung cancer surgery. Case Rep. Surg. 2011, 2011:902062.
63. Adigun T., et al. Anesthetic and surgical predictors of treatment outcome in re-do craniotomy. J. Neurosci. Rural Pract. 2011, 2:137-140.
64. Laronga C., et al. The changing face of mastectomy: an oncologic and cosmetic perspective. Cancer Control 2012, 19:286-294.
65. Mangham D.C., Athanasou N.A. Guidelines for histopathological specimen examination and diagnostic reporting of primary bone tumours. Clin. Sarcoma Res. 2011, 1:6.
66. Dahm F., et al. Open and laparoscopic living donor nephrectomy in Switzerland: a retrospective assessment of clinical outcomes and the motivation to donate. Nephrol. Dial. Transplant. 2006, 21:2563-2568.
67. Billis A., et al. Influence of focal and diffuse extraprostatic extension and positive surgical margins on biochemical progression following radical prostatectomy. Int. Braz. J. Urol. 2012, 38:175-184.
68. Theodosopoulos T., et al. Right Kocher's incision: a feasible and effective incision for right hemicolectomy: a retrospective study. World J. Surg. Oncol. 2012, 10:101.
69. Yamamoto M., et al. Clinical outcomes of laparoscopic surgery for advanced transverse and descending colon cancer: a single-center experience. Surg. Endosc. 2012, 26:1566-1572.
70. Worthington, K. and Worthington, V. Worthington Enzyme Manual, Worthington Biochemical Corp.
71. Haraguchi N., et al. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 2010, 120:3326-3339.
72. Eramo A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15:504-514.
73. Phillips T.M., et al. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 2006, 98:1777-1785.
74. Muraglia A., et al. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J. Cell Sci. 2000, 113:1161-1166.
75. Dudas P.L., et al. BMP-7 fails to attenuate TGF-beta1-induced epithelial-to-mesenchymal transition in human proximal tubule epithelial cells. Nephrol. Dial. Transplant. 2009, 24:1406-1416.
76. Peehl D.M. Primary cell cultures as models of prostate cancer development. Endocr. Relat. Cancer 2005, 12:19-47.
77. Ricci-Vitiani L., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
78. Zhang S., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68:4311-4320.